The development of this SR provides an overview that highlights a wide range of therapeutic targets suitable for DM treatment, as indicated by in silico studies corroborated through subsequent in vivo assessments, highlighting mainly the following targets: GLUT-4, DPP-IV, and PPARγ. The gene discussed is SLC2A4; the disease is diabetes mellitus.